FLAME 30
Advanced Drug Delivery Systems: New Developments, New Technologies
Report Highlights
- The global market for advanced drug delivery systems amounted to $134.3 billion in 2008, and was projected to increase to $139 billion in 2009. The estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR) of 7.2% in the 5-year period.
- The largest segment of the market is targeted drug delivery, which reached $50.9 billion in 2009 and is expected to increase to $80.2 billion in 2014, for a CAGR of 9.5%.
- Sustained-release products have the second-largest market share, with estimated sales of $36.1 billion in 2009 and $45.8 billion in 2014, for a CAGR of 4.9%.
INTRODUCTION
STUDY OBJECTIVES
BCC’s goal in conducting this study is to provide an overview of the current and potential aspects of the global market for advanced drug delivery systems and its future direction, with an emphasis on newer techniques and products. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drug delivery systems, including the use of these products in therapeutic markets.
An overview of types of drug delivery systems is also examined along with sales figures over the 5 year period from 2009 to 2014. This study provides an overview of the drug delivery market, which BCC projects will grow at a compound annual growth rate (CAGR) of 7.2% over the forecast period 2009 through 2014.
The study presents market size and future trends, profiles market leaders, and analyzes factors affecting drug delivery markets and important products. The report also examines future trends in drug delivery technology, the basic principles underlying different systems, and their applications. Companies manufacturing and selling the drug delivery products are also profiled. Revenues have been broken down by the type of drug delivery systems and by different regions.
Our key objective is to present a comprehensive analysis of the current market and the future direction of the advanced drug delivery systems.
REASONS FOR DOING THIS STUDY
The drug delivery market is changing drastically due to the introduction of new techniques and routes of delivery. R&D spending, along with increasing competition, patent expiries, new technologies, an international marketplace, and a changing customer base, is creating a new kind of market for drug delivery systems. This study looks at almost all the systems affected by these factors.
This is a very complex market, where many technologies are combined together to produce a better delivery system, thus creating niche markets with very specialized applications. The use of liposomes, polymers, etc. in the sustained-release oral/injectable drug delivery market is a good example. Prodrugs, PEGylation, nanoparticles, and liposomes are significant new markets.
Acquisition strategies and collaborations by companies are also covered in this report, for example, the acquisition of the Pulmonary Division of Nektar Therapeutics by Novartis. This study also discusses the strength and weaknesses of drug development market in light of the new technologies, growing competition, and changing customer needs.
INTENDED AUDIENCE
The report consolidates much of the information on new products and new technologies in the drug delivery industry. The study contributes to understanding market growth and decline in drug delivery market from the point of view of the manufacturer and user. This study will be of interest to manufacturers and end-users in the pharmaceutical and biotechnology industries, and to companies involved in R&D for drug delivery systems and new drugs.
SCOPE OF THE STUDY
This study encompasses the major types of drug delivery systems used in the health industry. BCC analyzes each technology and looks at the manufacturers, their new products, sales estimates, market projections, and some market share information. BCC analyzes the industry on a worldwide basis. Patents for drug delivery technologies are also studied by year, country, and assignee. The Food and Drug Administration (FDA) approvals for the past 5 years have been covered. New developments in this field have been examined in detail, including those that comprise a part of individual company profiles.
METHODOLOGY
Both primary and secondary research methods were used in this report. A comprehensive search of the literature was conducted. The literature included technical newsletters and journals as well as many other sources. The data were collected through interviews and correspondence with various pharmaceutical/ biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. We gathered the data from these industries, spoke with officials, and consulted newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and government sources.
ABOUT THE AUTHOR
Shalini Shahani Dewan holds a Masters Degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shahani was awarded a gold medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are: Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs, Implants and Devices; Imaging Reagents; Contract Manufacturing, Research and Packaging; The Dynamic Media, Sera and Reagent Market in Biotechnology;Opportunities in Chiral Technology;Behavioral and Emotional Disorders in Children and Adolescents; and Pharmaceutical Regulatory Industry; and many more.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Report Highlights
-
The U.S. sales of advanced drug delivery systems were over $54.2 billion in 2004. In 2005 they reached $64.1 billion and will eventually grow to $74.4 billion by the end of 2006. Over 5 years, this market will continue to grow at an average annual growth rate (AAGR) of 15.6% to reach $153.5 billion by 2011.
-
The largest sector of the market consists of sustained release/implants/transdermal drug delivery systems, with more than 50% of the total U.S. market in 2005. Through the forecast period this sector will gradually give way to targeted drug delivery systems, which should control almost 48% of the market in 2011.
-
Targeted drug delivery has the highest growth rate, with a 23.3% AAGR through 2011. The next highest are transmucosal drug delivery systems, with 15.3%.
Report Highlights
- The U.S. market for drug delivery systems in 2002 was $38.8 billion, and is expected to rise at an average annual growth rate (AAGR) of 11.3% and reach $74.5 billion by 2008.
- The sustained release (oral, injectable and topical) dosage form market is rising at an AAGR of 9.7% is expected to reach $34.1 billion by 2008.
- The transmucosal market is expected to grow at an AAGR of 12.8% and reach $17.7 billion by 2008.
- The market for targeted delivery systems was $7.3 billion in 2002 and will reach $15.5 billion by 2008.
- Transdermal systems and implants and IUDs are expected to climb at AAGRs of 11.1% and 12.4%, respectively.
Report Highlights
- Despite the complaints of health care being too expensive, the U.S. pharmaceutical industry is expected to offer increasing opportunities for advanced drug delivery systems, with the U.S. market for the systems estimated at $16.3 billion in 2000. The efficacy, safety, and convenience of the technologies should maintain average annual growth of 10.9% over the next five years, when sales are predicted to be about $27.4 billion.
- At $13.8 billion in estimated 2000 manufacturers' sales, standard controlled release technologies (microencapsulation, polymer/membrane, and coatings) dominate the market for advanced drug delivery systems. The intense competition in generic products is stimulating growth (7.2%), especially in oral formats, both osmotic and microencapsulated. Demand for injected sustained release products is also spurring growth. The widespread interest in controlled released systems should result in sales reaching $19.6 billion in five years.
